Drug intelligence / Profile preview

TNX-3800

Development stage: Preclinical
Lead developer: Tonix Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

TNX-3800 is a set of humanized anti-SARS-CoV-2 monoclonal antibodies licensed by Tonix Pharmaceuticals from Curia. These antibodies target the SARS-CoV-2 spike protein and are designed to treat or prevent COVID-19, particularly in immunocompromised individuals who may not respond adequately to vaccines. The antibodies were developed using Curia's technology to create candidates that are more resistant to viral evasion by new variants.

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on TNX-3800.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TNX-3800.

Explore the full profile